Richard Jackson
Concepts (490)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Protein Biosynthesis | 20 | 2012 | 253 | 3.340 |
Why?
| RNA, Viral | 15 | 2013 | 125 | 2.690 |
Why?
| Ribosomes | 14 | 2013 | 36 | 1.880 |
Why?
| Public Health | 8 | 2024 | 204 | 1.800 |
Why?
| RNA, Messenger | 10 | 2014 | 1105 | 1.490 |
Why?
| Peptide Chain Initiation, Translational | 10 | 2013 | 15 | 1.470 |
Why?
| Polypyrimidine Tract-Binding Protein | 7 | 2014 | 10 | 1.460 |
Why?
| Environment Design | 8 | 2024 | 25 | 1.200 |
Why?
| Rhinovirus | 3 | 2010 | 22 | 0.900 |
Why?
| Nucleic Acid Conformation | 14 | 2013 | 83 | 0.890 |
Why?
| Public Policy | 3 | 2015 | 38 | 0.820 |
Why?
| Environmental Health | 3 | 2011 | 12 | 0.730 |
Why?
| RNA-Binding Proteins | 5 | 2012 | 123 | 0.660 |
Why?
| 5' Untranslated Regions | 5 | 2011 | 31 | 0.650 |
Why?
| Environment | 2 | 2011 | 84 | 0.640 |
Why?
| City Planning | 5 | 2009 | 6 | 0.640 |
Why?
| Ligaments | 1 | 2017 | 12 | 0.610 |
Why?
| Ribs | 1 | 2017 | 15 | 0.610 |
Why?
| Chest Pain | 1 | 2017 | 53 | 0.600 |
Why?
| Binding Sites | 10 | 2014 | 374 | 0.600 |
Why?
| MicroRNAs | 4 | 2011 | 353 | 0.580 |
Why?
| Peptide Chain Termination, Translational | 4 | 2011 | 4 | 0.570 |
Why?
| Vinblastine | 1 | 2017 | 23 | 0.570 |
Why?
| Gene Expression Regulation | 4 | 2011 | 976 | 0.570 |
Why?
| Humans | 68 | 2024 | 49974 | 0.560 |
Why?
| Base Sequence | 14 | 2011 | 643 | 0.560 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 2017 | 69 | 0.550 |
Why?
| Carcinoma, Transitional Cell | 1 | 2017 | 52 | 0.550 |
Why?
| Encephalomyocarditis virus | 3 | 2011 | 3 | 0.530 |
Why?
| Molecular Sequence Data | 13 | 2011 | 792 | 0.530 |
Why?
| Renewable Energy | 1 | 2015 | 1 | 0.520 |
Why?
| Biofuels | 1 | 2015 | 4 | 0.510 |
Why?
| Vertebrates | 2 | 2013 | 11 | 0.510 |
Why?
| Urinary Bladder Neoplasms | 1 | 2017 | 155 | 0.510 |
Why?
| Picornaviridae | 2 | 2011 | 2 | 0.490 |
Why?
| DNA-Binding Proteins | 3 | 2007 | 427 | 0.480 |
Why?
| Eukaryotic Cells | 2 | 2012 | 17 | 0.480 |
Why?
| Open Reading Frames | 5 | 2012 | 55 | 0.450 |
Why?
| Public Health Administration | 2 | 2012 | 81 | 0.450 |
Why?
| Viral Proteins | 4 | 2009 | 155 | 0.440 |
Why?
| Eukaryotic Initiation Factors | 2 | 2010 | 5 | 0.430 |
Why?
| Eukaryotic Initiation Factor-4G | 2 | 2010 | 4 | 0.430 |
Why?
| Pestivirus | 2 | 2002 | 2 | 0.430 |
Why?
| Poliovirus | 2 | 2010 | 10 | 0.430 |
Why?
| Codon, Initiator | 7 | 2011 | 9 | 0.400 |
Why?
| Foot-and-Mouth Disease Virus | 1 | 2011 | 1 | 0.400 |
Why?
| Social Environment | 2 | 2012 | 80 | 0.390 |
Why?
| Environmental Exposure | 2 | 2002 | 199 | 0.360 |
Why?
| Eukaryota | 1 | 2010 | 11 | 0.360 |
Why?
| Pancreatic Neoplasms | 2 | 2022 | 208 | 0.350 |
Why?
| Health Policy | 1 | 2011 | 153 | 0.350 |
Why?
| Obesity | 2 | 2011 | 1113 | 0.340 |
Why?
| Virus Replication | 1 | 2010 | 140 | 0.320 |
Why?
| Residence Characteristics | 2 | 2024 | 151 | 0.320 |
Why?
| Social Conditions | 1 | 2008 | 8 | 0.310 |
Why?
| Calicivirus, Feline | 1 | 2007 | 2 | 0.310 |
Why?
| Models, Genetic | 2 | 2007 | 170 | 0.300 |
Why?
| RNA Caps | 1 | 2007 | 3 | 0.300 |
Why?
| Animals | 20 | 2013 | 13187 | 0.300 |
Why?
| Adolescent | 15 | 2017 | 6356 | 0.290 |
Why?
| Research | 2 | 2005 | 110 | 0.290 |
Why?
| Life Style | 1 | 2008 | 140 | 0.290 |
Why?
| Peptic Ulcer Perforation | 1 | 2006 | 4 | 0.290 |
Why?
| Abdomen, Acute | 1 | 2006 | 6 | 0.290 |
Why?
| Urban Health | 2 | 2003 | 31 | 0.290 |
Why?
| United States | 11 | 2015 | 4860 | 0.290 |
Why?
| Stomach Ulcer | 1 | 2006 | 7 | 0.290 |
Why?
| Gastroenteritis | 1 | 2006 | 17 | 0.280 |
Why?
| Community Health Planning | 2 | 2003 | 28 | 0.280 |
Why?
| Protein Structure, Tertiary | 4 | 2014 | 253 | 0.280 |
Why?
| Gastrointestinal Diseases | 2 | 2008 | 126 | 0.280 |
Why?
| Health Promotion | 4 | 2013 | 271 | 0.280 |
Why?
| Child Welfare | 2 | 2007 | 54 | 0.270 |
Why?
| Eosinophilia | 1 | 2006 | 37 | 0.270 |
Why?
| Child | 20 | 2017 | 6847 | 0.270 |
Why?
| Bacterial Translocation | 4 | 2009 | 16 | 0.260 |
Why?
| Health Priorities | 2 | 2024 | 19 | 0.260 |
Why?
| Mental Health | 1 | 2008 | 219 | 0.260 |
Why?
| Genes, Neurofibromatosis 1 | 1 | 2005 | 3 | 0.260 |
Why?
| Neurofibromatoses | 1 | 2005 | 5 | 0.250 |
Why?
| Laparoscopy | 4 | 2013 | 170 | 0.250 |
Why?
| Nerve Sheath Neoplasms | 1 | 2005 | 20 | 0.250 |
Why?
| Transcription, Genetic | 3 | 2003 | 369 | 0.250 |
Why?
| Pregnancy, Twin | 1 | 2024 | 8 | 0.240 |
Why?
| Probiotics | 3 | 2009 | 21 | 0.240 |
Why?
| Rectal Neoplasms | 1 | 2005 | 51 | 0.240 |
Why?
| Fetal Growth Retardation | 1 | 2024 | 43 | 0.240 |
Why?
| Female | 26 | 2024 | 26472 | 0.240 |
Why?
| Child, Preschool | 14 | 2017 | 3871 | 0.230 |
Why?
| Mammals | 3 | 2010 | 56 | 0.230 |
Why?
| Male | 26 | 2024 | 25241 | 0.230 |
Why?
| Rain | 1 | 2003 | 5 | 0.230 |
Why?
| Water Pollutants | 1 | 2003 | 8 | 0.230 |
Why?
| Water Supply | 1 | 2003 | 22 | 0.230 |
Why?
| Water Microbiology | 1 | 2003 | 29 | 0.230 |
Why?
| Feasibility Studies | 2 | 2024 | 375 | 0.220 |
Why?
| Environmental Pollution | 2 | 2003 | 11 | 0.220 |
Why?
| Public Health Practice | 1 | 2003 | 41 | 0.220 |
Why?
| Retrospective Studies | 13 | 2017 | 6108 | 0.220 |
Why?
| Regulatory Sequences, Ribonucleic Acid | 1 | 2002 | 6 | 0.220 |
Why?
| Cryogels | 1 | 2022 | 1 | 0.210 |
Why?
| Models, Econometric | 1 | 2002 | 12 | 0.210 |
Why?
| Exercise | 2 | 2015 | 495 | 0.210 |
Why?
| Carcinoma, Pancreatic Ductal | 1 | 2022 | 31 | 0.210 |
Why?
| Lead | 1 | 2002 | 33 | 0.210 |
Why?
| Goiter, Endemic | 1 | 2002 | 1 | 0.200 |
Why?
| Nuclear Reactors | 1 | 2002 | 2 | 0.200 |
Why?
| Iodine | 1 | 2002 | 10 | 0.200 |
Why?
| Radioactive Hazard Release | 1 | 2002 | 14 | 0.200 |
Why?
| Genetic Predisposition to Disease | 1 | 2005 | 510 | 0.200 |
Why?
| Sodium Chloride, Dietary | 1 | 2002 | 33 | 0.200 |
Why?
| Neoplasms, Radiation-Induced | 1 | 2002 | 38 | 0.200 |
Why?
| Rectum | 2 | 2017 | 54 | 0.200 |
Why?
| Income | 1 | 2002 | 99 | 0.200 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2024 | 549 | 0.200 |
Why?
| Disaster Planning | 1 | 2002 | 37 | 0.200 |
Why?
| Fundoplication | 2 | 2013 | 19 | 0.190 |
Why?
| Biomedical Research | 1 | 2024 | 237 | 0.190 |
Why?
| Aortic Aneurysm, Abdominal | 1 | 2021 | 51 | 0.190 |
Why?
| Hyperthermia, Induced | 1 | 2022 | 117 | 0.190 |
Why?
| Computer Simulation | 1 | 2021 | 280 | 0.190 |
Why?
| Treatment Outcome | 11 | 2021 | 5141 | 0.180 |
Why?
| Models, Molecular | 3 | 2012 | 338 | 0.180 |
Why?
| Cognition Disorders | 1 | 2002 | 218 | 0.180 |
Why?
| Blood Vessel Prosthesis Implantation | 1 | 2021 | 120 | 0.180 |
Why?
| Influenza B virus | 2 | 2011 | 6 | 0.180 |
Why?
| Infant | 13 | 2017 | 3567 | 0.180 |
Why?
| Reticulocytes | 3 | 2011 | 9 | 0.170 |
Why?
| Cohort Studies | 7 | 2022 | 1422 | 0.170 |
Why?
| Rabbits | 7 | 2011 | 370 | 0.170 |
Why?
| Codon | 2 | 2010 | 47 | 0.170 |
Why?
| Endovascular Procedures | 1 | 2021 | 173 | 0.160 |
Why?
| Genome, Viral | 2 | 2011 | 79 | 0.160 |
Why?
| Pyloric Stenosis | 2 | 2009 | 6 | 0.160 |
Why?
| Diabetes Mellitus | 1 | 2022 | 285 | 0.160 |
Why?
| Infant, Newborn | 9 | 2024 | 2772 | 0.160 |
Why?
| Sequence Alignment | 2 | 2009 | 121 | 0.150 |
Why?
| Amino Acid Sequence | 3 | 2009 | 585 | 0.150 |
Why?
| Ireland | 1 | 2017 | 12 | 0.140 |
Why?
| Vagina | 1 | 2017 | 45 | 0.140 |
Why?
| Syndrome | 1 | 2017 | 237 | 0.140 |
Why?
| Urothelium | 1 | 2017 | 18 | 0.140 |
Why?
| Lasers, Solid-State | 1 | 2017 | 32 | 0.140 |
Why?
| Alternative Splicing | 2 | 2014 | 56 | 0.140 |
Why?
| Walking | 2 | 2015 | 94 | 0.140 |
Why?
| Aged | 6 | 2024 | 9310 | 0.140 |
Why?
| Wounds, Nonpenetrating | 2 | 2008 | 81 | 0.140 |
Why?
| Disease-Free Survival | 1 | 2017 | 454 | 0.130 |
Why?
| Food, Formulated | 2 | 2008 | 42 | 0.130 |
Why?
| Vascular Malformations | 1 | 2017 | 98 | 0.130 |
Why?
| Catheterization | 2 | 2008 | 96 | 0.130 |
Why?
| Breast Neoplasms | 1 | 2024 | 1174 | 0.130 |
Why?
| Postoperative Complications | 4 | 2021 | 984 | 0.130 |
Why?
| Bicycling | 1 | 2015 | 25 | 0.120 |
Why?
| Public Opinion | 1 | 2015 | 20 | 0.120 |
Why?
| Bone Neoplasms | 1 | 2017 | 179 | 0.120 |
Why?
| Middle Aged | 6 | 2024 | 12069 | 0.120 |
Why?
| Adult | 9 | 2024 | 13236 | 0.120 |
Why?
| Lung | 2 | 2009 | 486 | 0.120 |
Why?
| RNA Precursors | 1 | 2014 | 9 | 0.120 |
Why?
| Codon, Terminator | 3 | 2009 | 8 | 0.120 |
Why?
| Gastric Fistula | 1 | 2013 | 10 | 0.120 |
Why?
| Enteral Nutrition | 3 | 2008 | 147 | 0.110 |
Why?
| Cutaneous Fistula | 1 | 2013 | 15 | 0.110 |
Why?
| Gastric Mucosa | 3 | 2009 | 47 | 0.110 |
Why?
| Gastrostomy | 1 | 2013 | 55 | 0.110 |
Why?
| Mutagenesis, Site-Directed | 2 | 2004 | 99 | 0.110 |
Why?
| HeLa Cells | 3 | 2010 | 250 | 0.110 |
Why?
| Peptide Initiation Factors | 1 | 2013 | 3 | 0.110 |
Why?
| Communication | 1 | 2015 | 246 | 0.110 |
Why?
| Liver Neoplasms | 1 | 2017 | 326 | 0.110 |
Why?
| Animals, Newborn | 3 | 2009 | 367 | 0.110 |
Why?
| Classical swine fever virus | 2 | 2002 | 2 | 0.110 |
Why?
| Mutation | 4 | 2014 | 1294 | 0.110 |
Why?
| Prospective Studies | 5 | 2024 | 2364 | 0.100 |
Why?
| Protein Binding | 3 | 2014 | 660 | 0.100 |
Why?
| Mobility Limitation | 1 | 2012 | 21 | 0.100 |
Why?
| Local Government | 1 | 2012 | 23 | 0.100 |
Why?
| Physician's Role | 2 | 2009 | 48 | 0.100 |
Why?
| Kobuvirus | 1 | 2011 | 1 | 0.100 |
Why?
| Regulatory Elements, Transcriptional | 1 | 2011 | 8 | 0.100 |
Why?
| Chloramphenicol O-Acetyltransferase | 1 | 2011 | 8 | 0.100 |
Why?
| Artificial Gene Fusion | 1 | 2011 | 7 | 0.100 |
Why?
| Enterobacter cloacae | 2 | 2009 | 5 | 0.100 |
Why?
| Stomach | 3 | 2009 | 80 | 0.100 |
Why?
| Genes, Reporter | 1 | 2011 | 89 | 0.100 |
Why?
| Poly A | 1 | 2011 | 11 | 0.100 |
Why?
| Follow-Up Studies | 6 | 2017 | 2182 | 0.100 |
Why?
| Organizational Objectives | 1 | 2011 | 33 | 0.100 |
Why?
| Leadership | 1 | 2012 | 101 | 0.090 |
Why?
| Life Expectancy | 1 | 2011 | 34 | 0.090 |
Why?
| Quality of Life | 2 | 2021 | 836 | 0.090 |
Why?
| Catheterization, Central Venous | 2 | 2002 | 86 | 0.090 |
Why?
| Spleen | 2 | 2009 | 172 | 0.090 |
Why?
| Kinetics | 2 | 2010 | 623 | 0.090 |
Why?
| Base Pairing | 1 | 2010 | 27 | 0.090 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2010 | 63 | 0.090 |
Why?
| Bromouracil | 1 | 2010 | 1 | 0.090 |
Why?
| Pseudouridine | 1 | 2010 | 1 | 0.090 |
Why?
| Trinucleotide Repeats | 1 | 2010 | 4 | 0.090 |
Why?
| Uridine | 1 | 2010 | 5 | 0.090 |
Why?
| Cell Extracts | 1 | 2010 | 5 | 0.090 |
Why?
| Uridine Triphosphate | 1 | 2010 | 15 | 0.090 |
Why?
| Microtechnology | 1 | 2010 | 4 | 0.090 |
Why?
| Laparotomy | 2 | 2008 | 34 | 0.090 |
Why?
| RNA, Small Interfering | 2 | 2011 | 215 | 0.090 |
Why?
| Biopsy | 3 | 2009 | 584 | 0.090 |
Why?
| Hernia, Diaphragmatic | 1 | 2010 | 22 | 0.090 |
Why?
| Norovirus | 1 | 2009 | 3 | 0.090 |
Why?
| Point Mutation | 1 | 2010 | 65 | 0.090 |
Why?
| Meconium | 1 | 2009 | 4 | 0.090 |
Why?
| Enema | 1 | 2009 | 9 | 0.090 |
Why?
| Transportation | 2 | 2015 | 30 | 0.090 |
Why?
| Ileus | 1 | 2009 | 15 | 0.090 |
Why?
| Intestinal Atresia | 1 | 2009 | 5 | 0.090 |
Why?
| Viruses | 1 | 2009 | 21 | 0.090 |
Why?
| Enterobacteriaceae Infections | 1 | 2009 | 15 | 0.080 |
Why?
| Food, Fortified | 1 | 2009 | 32 | 0.080 |
Why?
| Models, Biological | 3 | 2008 | 727 | 0.080 |
Why?
| Risk Assessment | 4 | 2008 | 1259 | 0.080 |
Why?
| Models, Educational | 1 | 2009 | 30 | 0.080 |
Why?
| Pyloric Stenosis, Hypertrophic | 1 | 2009 | 21 | 0.080 |
Why?
| Peritoneal Dialysis | 1 | 2008 | 33 | 0.080 |
Why?
| Health Behavior | 2 | 2015 | 254 | 0.080 |
Why?
| Suture Techniques | 1 | 2008 | 59 | 0.080 |
Why?
| Epithelial Cells | 1 | 2010 | 209 | 0.080 |
Why?
| Snake Bites | 1 | 2008 | 16 | 0.080 |
Why?
| Multiple Trauma | 1 | 2008 | 32 | 0.080 |
Why?
| Equipment Contamination | 3 | 2002 | 18 | 0.080 |
Why?
| Viral Structural Proteins | 1 | 2007 | 4 | 0.080 |
Why?
| Genes | 1 | 2007 | 33 | 0.080 |
Why?
| Sequence Homology, Nucleic Acid | 1 | 2007 | 48 | 0.080 |
Why?
| Cats | 1 | 2007 | 79 | 0.080 |
Why?
| Robotics | 1 | 2008 | 43 | 0.080 |
Why?
| Time Factors | 4 | 2010 | 2903 | 0.080 |
Why?
| RNA Cap Analogs | 1 | 2007 | 1 | 0.080 |
Why?
| Diagnosis, Differential | 3 | 2006 | 1037 | 0.080 |
Why?
| Pheochromocytoma | 1 | 2008 | 35 | 0.080 |
Why?
| Electrophoretic Mobility Shift Assay | 1 | 2007 | 73 | 0.080 |
Why?
| Telephone | 1 | 2008 | 70 | 0.070 |
Why?
| Drosophila | 1 | 2007 | 17 | 0.070 |
Why?
| Adrenal Gland Neoplasms | 1 | 2008 | 51 | 0.070 |
Why?
| Polymers | 2 | 2022 | 40 | 0.070 |
Why?
| Intestinal Obstruction | 1 | 2007 | 36 | 0.070 |
Why?
| United States Government Agencies | 1 | 2007 | 2 | 0.070 |
Why?
| Endosonography | 1 | 2008 | 92 | 0.070 |
Why?
| Ecology | 1 | 2007 | 17 | 0.070 |
Why?
| Cystic Fibrosis | 1 | 2009 | 147 | 0.070 |
Why?
| Cross-Sectional Studies | 3 | 2024 | 1557 | 0.070 |
Why?
| Aftercare | 1 | 2008 | 75 | 0.070 |
Why?
| Surgical Procedures, Operative | 1 | 2008 | 63 | 0.070 |
Why?
| Enzymes, Immobilized | 1 | 2007 | 4 | 0.070 |
Why?
| Eukaryotic Initiation Factor-4E | 1 | 2007 | 4 | 0.070 |
Why?
| Disulfides | 1 | 2007 | 17 | 0.070 |
Why?
| Aging | 1 | 2012 | 687 | 0.070 |
Why?
| Biosensing Techniques | 1 | 2007 | 25 | 0.070 |
Why?
| Extracorporeal Membrane Oxygenation | 1 | 2010 | 287 | 0.070 |
Why?
| RNA Stability | 1 | 2007 | 24 | 0.070 |
Why?
| Hemodynamics | 1 | 2008 | 228 | 0.070 |
Why?
| Cell Line | 3 | 2008 | 1000 | 0.070 |
Why?
| Duodenum | 1 | 2006 | 35 | 0.070 |
Why?
| Aorta, Abdominal | 1 | 2006 | 41 | 0.070 |
Why?
| Abdominal Injuries | 1 | 2006 | 36 | 0.070 |
Why?
| Lipoma | 1 | 2006 | 18 | 0.070 |
Why?
| Caenorhabditis elegans | 1 | 2007 | 138 | 0.070 |
Why?
| Glycoproteins | 1 | 2007 | 115 | 0.070 |
Why?
| Endoscopy, Gastrointestinal | 1 | 2006 | 73 | 0.070 |
Why?
| Arterial Occlusive Diseases | 1 | 2006 | 79 | 0.070 |
Why?
| RNA, Ribosomal, 18S | 3 | 2011 | 8 | 0.070 |
Why?
| Curriculum | 1 | 2009 | 401 | 0.070 |
Why?
| Liver | 2 | 2009 | 1115 | 0.070 |
Why?
| Clinical Competence | 1 | 2009 | 393 | 0.060 |
Why?
| Gold | 1 | 2007 | 136 | 0.060 |
Why?
| Down-Regulation | 1 | 2007 | 348 | 0.060 |
Why?
| Mesenchymoma | 1 | 2005 | 3 | 0.060 |
Why?
| Neuroectodermal Tumors, Primitive | 1 | 2005 | 4 | 0.060 |
Why?
| Rhabdomyosarcoma | 1 | 2005 | 13 | 0.060 |
Why?
| Leiomyosarcoma | 1 | 2005 | 23 | 0.060 |
Why?
| Body Weight | 2 | 2004 | 513 | 0.060 |
Why?
| Diet | 1 | 2009 | 566 | 0.060 |
Why?
| Ultrasonography | 4 | 2009 | 436 | 0.060 |
Why?
| Aircraft | 1 | 2004 | 9 | 0.060 |
Why?
| Twins, Monozygotic | 1 | 2024 | 17 | 0.060 |
Why?
| Watchful Waiting | 1 | 2024 | 27 | 0.060 |
Why?
| Play and Playthings | 1 | 2004 | 12 | 0.060 |
Why?
| Costs and Cost Analysis | 1 | 2004 | 95 | 0.060 |
Why?
| Organothiophosphorus Compounds | 1 | 2004 | 6 | 0.060 |
Why?
| Firearms | 1 | 2004 | 19 | 0.060 |
Why?
| Insecticides | 1 | 2004 | 15 | 0.060 |
Why?
| Wounds, Gunshot | 1 | 2004 | 32 | 0.060 |
Why?
| Water Movements | 1 | 2003 | 2 | 0.060 |
Why?
| Healthy People Programs | 1 | 2003 | 4 | 0.060 |
Why?
| Social Change | 1 | 2003 | 5 | 0.060 |
Why?
| Waste Disposal, Fluid | 1 | 2003 | 6 | 0.060 |
Why?
| Automobiles | 1 | 2003 | 14 | 0.060 |
Why?
| Rectal Diseases | 1 | 2003 | 10 | 0.060 |
Why?
| Structure-Activity Relationship | 1 | 2004 | 395 | 0.050 |
Why?
| Digestive System Surgical Procedures | 1 | 2003 | 33 | 0.050 |
Why?
| Eukaryotic Initiation Factor-4A | 1 | 2002 | 1 | 0.050 |
Why?
| Defective Viruses | 1 | 2002 | 1 | 0.050 |
Why?
| Prokaryotic Cells | 1 | 2002 | 8 | 0.050 |
Why?
| Risk Factors | 3 | 2021 | 3613 | 0.050 |
Why?
| Cost of Illness | 1 | 2003 | 117 | 0.050 |
Why?
| Gastroschisis | 1 | 2003 | 38 | 0.050 |
Why?
| GATA6 Transcription Factor | 1 | 2022 | 3 | 0.050 |
Why?
| GATA4 Transcription Factor | 1 | 2022 | 11 | 0.050 |
Why?
| Genetic Engineering | 1 | 2002 | 24 | 0.050 |
Why?
| Hydrochloric Acid | 1 | 2002 | 2 | 0.050 |
Why?
| Citric Acid | 1 | 2002 | 16 | 0.050 |
Why?
| Disease Reservoirs | 1 | 2002 | 4 | 0.050 |
Why?
| Magnetic Phenomena | 1 | 2022 | 6 | 0.050 |
Why?
| Multicenter Studies as Topic | 1 | 2022 | 84 | 0.050 |
Why?
| Occupations | 1 | 2002 | 17 | 0.050 |
Why?
| Pancreas | 1 | 2022 | 70 | 0.050 |
Why?
| Gels | 1 | 2022 | 21 | 0.050 |
Why?
| Fibrin | 1 | 2002 | 10 | 0.050 |
Why?
| Length of Stay | 4 | 2008 | 619 | 0.050 |
Why?
| Empyema | 1 | 2002 | 7 | 0.050 |
Why?
| Republic of Belarus | 1 | 2002 | 1 | 0.050 |
Why?
| Russia | 1 | 2002 | 10 | 0.050 |
Why?
| Ukraine | 1 | 2002 | 6 | 0.050 |
Why?
| Intelligence | 1 | 2002 | 59 | 0.050 |
Why?
| Drug Resistance, Bacterial | 1 | 2002 | 71 | 0.050 |
Why?
| Deficiency Diseases | 1 | 2002 | 14 | 0.050 |
Why?
| Reference Values | 3 | 2008 | 310 | 0.050 |
Why?
| State Medicine | 1 | 2021 | 13 | 0.050 |
Why?
| Hepacivirus | 1 | 2002 | 104 | 0.050 |
Why?
| Critical Pathways | 1 | 2002 | 39 | 0.050 |
Why?
| Bacterial Infections | 1 | 2002 | 95 | 0.050 |
Why?
| Thyroid Gland | 1 | 2002 | 73 | 0.050 |
Why?
| Cross Infection | 1 | 2002 | 95 | 0.050 |
Why?
| Forecasting | 1 | 2002 | 150 | 0.050 |
Why?
| Incidence | 3 | 2013 | 1003 | 0.050 |
Why?
| Sensitivity and Specificity | 3 | 2008 | 861 | 0.050 |
Why?
| Intestines | 1 | 2002 | 176 | 0.050 |
Why?
| Cost-Benefit Analysis | 1 | 2002 | 274 | 0.050 |
Why?
| Smoking | 1 | 2005 | 511 | 0.050 |
Why?
| Early Detection of Cancer | 1 | 2022 | 169 | 0.050 |
Why?
| Congenital Abnormalities | 1 | 2002 | 112 | 0.050 |
Why?
| Thyroid Neoplasms | 1 | 2002 | 110 | 0.040 |
Why?
| Proteins | 1 | 2003 | 342 | 0.040 |
Why?
| RNA | 2 | 2012 | 170 | 0.040 |
Why?
| Acetaminophen | 1 | 2022 | 283 | 0.040 |
Why?
| Mice | 4 | 2011 | 5739 | 0.040 |
Why?
| Sepsis | 1 | 2002 | 220 | 0.040 |
Why?
| Radiography | 2 | 2009 | 489 | 0.040 |
Why?
| Probability | 2 | 2008 | 164 | 0.040 |
Why?
| Gene Expression Profiling | 1 | 2022 | 1032 | 0.040 |
Why?
| Arkansas | 3 | 2010 | 1977 | 0.040 |
Why?
| Intestinal Mucosa | 2 | 2009 | 225 | 0.040 |
Why?
| Pregnancy | 1 | 2024 | 2607 | 0.040 |
Why?
| Young Adult | 2 | 2017 | 3958 | 0.030 |
Why?
| Injury Severity Score | 2 | 2008 | 159 | 0.030 |
Why?
| Colon | 2 | 2009 | 98 | 0.030 |
Why?
| Models, Animal | 2 | 2009 | 233 | 0.030 |
Why?
| Los Angeles | 1 | 2015 | 30 | 0.030 |
Why?
| Reoperation | 2 | 2008 | 454 | 0.030 |
Why?
| Sex Factors | 2 | 2008 | 691 | 0.030 |
Why?
| Data Collection | 1 | 2015 | 279 | 0.030 |
Why?
| Disease Models, Animal | 2 | 2009 | 1455 | 0.030 |
Why?
| ROC Curve | 1 | 2013 | 232 | 0.030 |
Why?
| Mutagenesis | 2 | 2003 | 60 | 0.030 |
Why?
| Age Factors | 2 | 2008 | 1087 | 0.030 |
Why?
| Staphylococcus epidermidis | 2 | 2002 | 12 | 0.030 |
Why?
| Planning Techniques | 1 | 2012 | 9 | 0.030 |
Why?
| Automobile Driving | 1 | 2012 | 22 | 0.030 |
Why?
| Exons | 1 | 2012 | 95 | 0.030 |
Why?
| California | 1 | 2012 | 87 | 0.030 |
Why?
| Health Plan Implementation | 1 | 2012 | 36 | 0.020 |
Why?
| Social Class | 1 | 2012 | 94 | 0.020 |
Why?
| Gene Expression Regulation, Viral | 1 | 2011 | 48 | 0.020 |
Why?
| Micrococcal Nuclease | 1 | 2011 | 7 | 0.020 |
Why?
| RNA-Induced Silencing Complex | 1 | 2011 | 2 | 0.020 |
Why?
| Eukaryotic Initiation Factor-3 | 1 | 2011 | 1 | 0.020 |
Why?
| RNA, Ribosomal | 1 | 2011 | 20 | 0.020 |
Why?
| Oligonucleotides, Antisense | 1 | 2011 | 28 | 0.020 |
Why?
| Nucleotide Motifs | 1 | 2011 | 24 | 0.020 |
Why?
| Logistic Models | 1 | 2013 | 888 | 0.020 |
Why?
| Oligonucleotides | 1 | 2011 | 80 | 0.020 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 488 | 0.020 |
Why?
| Silicon | 1 | 2010 | 8 | 0.020 |
Why?
| Immunoassay | 1 | 2010 | 20 | 0.020 |
Why?
| Edeine | 1 | 2009 | 1 | 0.020 |
Why?
| RNA, Complementary | 1 | 2009 | 3 | 0.020 |
Why?
| 5' Flanking Region | 1 | 2009 | 7 | 0.020 |
Why?
| Diatrizoate Meglumine | 1 | 2009 | 2 | 0.020 |
Why?
| Nucleotides | 1 | 2009 | 23 | 0.020 |
Why?
| Regulatory Sequences, Nucleic Acid | 1 | 2009 | 40 | 0.020 |
Why?
| Luciferases | 1 | 2009 | 50 | 0.020 |
Why?
| Phenotype | 2 | 2003 | 729 | 0.020 |
Why?
| Eukaryotic Initiation Factor-2 | 1 | 2009 | 18 | 0.020 |
Why?
| Saccharomyces cerevisiae | 1 | 2011 | 190 | 0.020 |
Why?
| Chronic Disease | 1 | 2012 | 567 | 0.020 |
Why?
| Hirschsprung Disease | 1 | 2009 | 3 | 0.020 |
Why?
| DNA, Single-Stranded | 1 | 2010 | 87 | 0.020 |
Why?
| Neurons | 2 | 2003 | 460 | 0.020 |
Why?
| Anastomosis, Surgical | 1 | 2009 | 66 | 0.020 |
Why?
| Birth Weight | 1 | 2009 | 120 | 0.020 |
Why?
| Staff Development | 1 | 2009 | 23 | 0.020 |
Why?
| Models, Theoretical | 1 | 2010 | 175 | 0.020 |
Why?
| Cecum | 1 | 2009 | 63 | 0.020 |
Why?
| Hydrogen-Ion Concentration | 1 | 2009 | 175 | 0.020 |
Why?
| Peritonitis | 1 | 2008 | 27 | 0.020 |
Why?
| Physical Examination | 1 | 2009 | 90 | 0.020 |
Why?
| Foreign-Body Migration | 1 | 2008 | 32 | 0.020 |
Why?
| Pelvis | 1 | 2008 | 68 | 0.020 |
Why?
| Preoperative Care | 1 | 2009 | 164 | 0.020 |
Why?
| Phenoxybenzamine | 1 | 2008 | 18 | 0.020 |
Why?
| Survival Analysis | 1 | 2010 | 653 | 0.020 |
Why?
| Sickness Impact Profile | 1 | 2008 | 28 | 0.020 |
Why?
| Host-Pathogen Interactions | 1 | 2009 | 134 | 0.020 |
Why?
| Phosphorylation | 1 | 2009 | 535 | 0.020 |
Why?
| Radiography, Abdominal | 1 | 2008 | 27 | 0.020 |
Why?
| Adrenalectomy | 1 | 2008 | 34 | 0.020 |
Why?
| Sex Distribution | 1 | 2008 | 134 | 0.020 |
Why?
| Age Distribution | 1 | 2008 | 168 | 0.020 |
Why?
| Interprofessional Relations | 1 | 2009 | 85 | 0.020 |
Why?
| Intestinal Volvulus | 1 | 2007 | 6 | 0.020 |
Why?
| Colony Count, Microbial | 1 | 2008 | 66 | 0.020 |
Why?
| Neurosurgery | 1 | 2008 | 32 | 0.020 |
Why?
| DNA Primers | 1 | 2008 | 207 | 0.020 |
Why?
| Gestational Age | 1 | 2009 | 421 | 0.020 |
Why?
| General Surgery | 1 | 2009 | 105 | 0.020 |
Why?
| Magnetic Resonance Imaging | 2 | 2006 | 1537 | 0.020 |
Why?
| Enterocolitis, Necrotizing | 1 | 2008 | 35 | 0.020 |
Why?
| Nurse's Role | 1 | 2008 | 68 | 0.020 |
Why?
| Safety | 1 | 2008 | 78 | 0.020 |
Why?
| Biopsy, Needle | 1 | 2008 | 183 | 0.020 |
Why?
| Horseradish Peroxidase | 1 | 2007 | 17 | 0.020 |
Why?
| Postoperative Care | 1 | 2008 | 102 | 0.020 |
Why?
| Chi-Square Distribution | 1 | 2007 | 280 | 0.020 |
Why?
| Random Allocation | 1 | 2008 | 281 | 0.020 |
Why?
| Carbohydrates | 1 | 2007 | 40 | 0.020 |
Why?
| Lymph Nodes | 1 | 2009 | 260 | 0.020 |
Why?
| Angioplasty | 1 | 2006 | 20 | 0.020 |
Why?
| Kidney Failure, Chronic | 1 | 2008 | 198 | 0.020 |
Why?
| Hospitals, Pediatric | 1 | 2008 | 239 | 0.020 |
Why?
| Hydrogen Peroxide | 1 | 2007 | 115 | 0.020 |
Why?
| Combined Modality Therapy | 1 | 2008 | 637 | 0.020 |
Why?
| Gene Expression | 1 | 2008 | 609 | 0.020 |
Why?
| Survival Rate | 1 | 2008 | 894 | 0.020 |
Why?
| Neoplasm Invasiveness | 1 | 2006 | 267 | 0.020 |
Why?
| Registries | 1 | 2008 | 522 | 0.020 |
Why?
| Neoplasm Staging | 1 | 2008 | 740 | 0.020 |
Why?
| Practice Guidelines as Topic | 1 | 2008 | 449 | 0.020 |
Why?
| Reproducibility of Results | 1 | 2009 | 1193 | 0.020 |
Why?
| Immunohistochemistry | 1 | 2008 | 973 | 0.020 |
Why?
| Case-Control Studies | 1 | 2008 | 1131 | 0.020 |
Why?
| Glucose | 1 | 2007 | 344 | 0.020 |
Why?
| Severity of Illness Index | 1 | 2008 | 945 | 0.020 |
Why?
| Algorithms | 1 | 2007 | 615 | 0.010 |
Why?
| Tissue Distribution | 1 | 2004 | 163 | 0.010 |
Why?
| Congresses as Topic | 1 | 2003 | 44 | 0.010 |
Why?
| Creatinine | 1 | 2004 | 139 | 0.010 |
Why?
| Rectal Fistula | 1 | 2003 | 1 | 0.010 |
Why?
| Housing | 1 | 2003 | 46 | 0.010 |
Why?
| Compartment Syndromes | 1 | 2003 | 16 | 0.010 |
Why?
| Apoptotic Protease-Activating Factor 1 | 1 | 2003 | 1 | 0.010 |
Why?
| Internship and Residency | 1 | 2009 | 443 | 0.010 |
Why?
| Ultraviolet Rays | 1 | 2003 | 51 | 0.010 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 102 | 0.010 |
Why?
| Cysts | 1 | 2003 | 51 | 0.010 |
Why?
| Amino Acid Motifs | 1 | 2002 | 56 | 0.010 |
Why?
| Enterobacter | 1 | 2002 | 6 | 0.010 |
Why?
| Vancomycin Resistance | 1 | 2002 | 5 | 0.010 |
Why?
| Enterococcus | 1 | 2002 | 10 | 0.010 |
Why?
| Neuroblastoma | 1 | 2002 | 52 | 0.010 |
Why?
| Methicillin Resistance | 1 | 2002 | 17 | 0.010 |
Why?
| Protein Conformation | 1 | 2003 | 166 | 0.010 |
Why?
| Disease Transmission, Infectious | 1 | 2002 | 13 | 0.010 |
Why?
| Venous Cutdown | 1 | 2002 | 2 | 0.010 |
Why?
| Food Contamination | 1 | 2002 | 40 | 0.010 |
Why?
| Bacterial Adhesion | 1 | 2002 | 15 | 0.010 |
Why?
| Subclavian Vein | 1 | 2002 | 10 | 0.010 |
Why?
| Transfection | 1 | 2003 | 354 | 0.010 |
Why?
| Thoracostomy | 1 | 2002 | 11 | 0.010 |
Why?
| Neoplasm Recurrence, Local | 1 | 2006 | 614 | 0.010 |
Why?
| Thoracic Surgery, Video-Assisted | 1 | 2002 | 11 | 0.010 |
Why?
| Gene Deletion | 1 | 2003 | 266 | 0.010 |
Why?
| Tumor Cells, Cultured | 1 | 2002 | 465 | 0.010 |
Why?
| Health Status | 1 | 2003 | 298 | 0.010 |
Why?
| Polymerase Chain Reaction | 1 | 2003 | 453 | 0.010 |
Why?
| Blotting, Western | 1 | 2003 | 601 | 0.010 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 595 | 0.010 |
Why?
| Tomography, X-Ray Computed | 1 | 2006 | 1159 | 0.010 |
Why?
| Equipment Design | 1 | 2002 | 284 | 0.010 |
Why?
| Dose-Response Relationship, Drug | 1 | 2003 | 1376 | 0.010 |
Why?
| Staphylococcus aureus | 1 | 2002 | 326 | 0.010 |
Why?
| Rats, Sprague-Dawley | 1 | 2002 | 1597 | 0.010 |
Why?
| Rats | 1 | 2002 | 3305 | 0.010 |
Why?
|
|
Jackson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|